TargetMol

Niceritrol

Product Code:
 
TAR-T19861
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T19861-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-2mg2mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-5mg5mg£160.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-1mL1 mL * 10 mM (in DMSO)£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-10mg10mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-25mg25mg£298.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-50mg50mg£413.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19861-100mg100mg£576.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Niceritrol is a niacin ester that reduces cholesterol and triglycerides in total plasma and in the VLD and LD lipoprotein fractions.
CAS:
5868-05-3
Formula:
C29H24N4O8
Molecular Weight:
556.531
Purity:
0.98
SMILES:
O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1

References

1. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med. 2003 Apr 1;114(5):347-53. 2. Yamamoto K, Fukushima N, Ozaki I, Setoguchi Y, Yanagita T, Sakai T. New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia. Artery. 1991;18(3):133-49. 3. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant. 1999 Mar;14(3):610-4. 4. Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. Thromb Res. 1985 Nov 15;40(4):543-53.